Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
The presence of CKD in cancer patients has been reported to be an independent risk factor for mortality. While the reason for this is uncertain, some reports suggest that patients are unable to receive appropriate cancer chemotherapy due to decreased kidney function. However, in recent years, molecular targeted drugs, including immune checkpoint inhibitors, which have relatively low nephrotoxicity, have become more common, making it important to clarify the impact of CKD on cancer treatment and prognosis in present day. The purpose of this study is to clarify whether CKD truly worsens cancer prognosis, whether this is due to differences in the rate of cancer chemotherapy, and whether the proportion of types of anticancer drugs administered differs depending on whether the patient has CKD, and to clarify the relationship between the presence of CKD, and the administration of cancer chemotherapy and renal prognosis in cancer patients.
We conducted a retrospective observational study using electronic medical record data from 657 patients with stage 4 solid tumors and hematopoietic malignancies who were registered at our hospital between March 2020 and September 2023. Cancer sites were classified into hematopoietic organs, genitourinary organs which are likely to directly affect renal function, and other solid organs. Cancer chemotherapy was classified into cytotoxic anticancer drugs and molecular targeted drugs, including immune checkpoint inhibitors. Logistic regression analysis was used to examine the relationship between CKD, and receipt of cancer chemotherapy and kidney prognosis, and survival analysis using the COX proportional hazards model was used to examine the relationship with life prognosis. Sex, age, serum albumin level, and performance status were used as covariates. Life prognosis was assessed by all-cause mortality and transition to palliative care, and kidney prognosis was assessed by a sustained decline in eGFR of 30% or more and the initiation of renal replacement therapy.
The study subjects included 239 patients with hematopoietic malignancies, 81 patients with genitourinary cancers, and 337 patients with other solid tumors. The mean follow-up period was 667 days, and 254 patients (38.7%) died or transitioned to palliative care. Contrary to previous speculation, the presence of CKD was not associated with the rate of cancer chemotherapy. For all cancer sites, CKD stage G3a or higher was not associated with death or transition to palliative care. However, for solid tumors other than genitourinary cancers, CKD stage G3b or higher was associated with a significantly higher risk of death or transition to palliative care (HR 2.04, 95% C.I. 1.09-3.80). Furthermore, for solid tumors other than genitourinary cancers, the risk factor for poor kidney prognosis was CKD stage G3a or higher (HR 3.06, 95% C.I. 1.08-8.73), which was not associated with the receipt of cancer chemotherapy.
Contrary to previous speculation, it maybe now possible that the coexistence of CKD G3a does not necessarily mean poor prognosis of cancer patients. Anticancer drugs with low nephrotoxicity are also becoming more common, and it is necessary to formulate treatment plans for cancer patients with CKD with careful consideration of the individual patient's condition and the characteristics of the anticancer drugs.
